Clinical Trial Update: Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pembrolizumab in combination with bevacizumab, with or without the anti-CD40 agonist CDX-1140, for recurrent ovarian, fallop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Carcinoma
• Ovarian Cancer
• Ovarian Clear Cell Adenocarcinoma
• Ovarian Endometrioid Adenocarcinoma
• Ovarian Serous Adenocarcinoma
• Peritoneal Carcinoma
• Platinum-resistant Ovarian Carcinoma
• Platinum-sensitive Ovarian Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CDX-1140
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Status: RECRUITING